Transfer of EBV-specific CTL to prevent EBV lymphoma post bone marrow transplant.
EBV-associated lymphoproliferative disorders (EBV-LPD) are a significant problem after hemopoietic stem cell transplantation from unrelated donors or mismatched family members. Risk factors include T-cell depletion, MHC mismatch, and intensity of immunosuppression. New therapeutic strategies involve cellular immunotherapy approaches and both donor T-cells and EBV-specific cytotoxic T lymphocytes (CTLs) have proven to be effective therapies. EBV-specific CTL has also proved to have a major impact on the incidence of this complication when used prophylactically.
Heslop
H E
HE
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas 77030, USA.
Perez
M
M
Benaim
E
E
Rochester
R
R
Brenner
M K
MK
Rooney
C M
CM
D000918:Antibody Specificity; D016026:Bone Marrow Transplantation; D004854:Herpesvirus 4, Human / Q000276:immunology*; D006801:Humans; D008223:Lymphoma / Q000276:immunology / Q000628:therapy / Q000821:virology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014181:Transplantation Immunology